Latest News

Amgen (NASDAQ:AMGN) presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to durvalumab maintenance treatment, improved survival outcomes for patients with extensive-stage small-cell lung cancer whose di

When you think “companies Berkshire Hathaway likes”, often we think of mature, almost iconic businesses that have produced consistent results for years. Bending Spoons, an acquirer of legacy digital assets, doesn’t really fit the mold. Today, though, Matt, Jon, and Tyler take a closer look at why Berkshire is buying this Milan-based business and why it may be closer to the prototypical Berkshire business. Plus, emptying the analyst notebook on earnings and distressed debt is hitting neoclouds

Advance Auto Parts is burning cash while Etsy generates $639 million in free cash flow, a stark divide that frames the real risk-reward trade-off.

Palantir stock has risen more than 700% over the last five years. Is a stock split in the cards?

Deposit discipline and share buybacks are amplifying per-share earnings as interest rates reset higher.

The company's gene-editing-focused platform looks promising.

Booking's 20% net margin and $9.1 billion in free cash flow stack against Five Below's aggressive 22.9% revenue growth.

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The INTerpath-001 trial met its primary endpoint of relapse-free survival and a key secondary endpoint of di

The stock is down 46% over the past year.

Owning the S&P 500 index isn't as diversified of a strategy as you might initially assume.

Oil prices are high, which is a relatively greater benefit to Occidental, but what happens when commodity prices fall?

Cybersecurity as it pertains to AI agents is rapidly becoming an issue that could make Ethereum more valuable.

Not all dividend payers are built the same.

Parabilis Medicines (NASDAQ:PBLS) presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society for Medical Oncology Congress in Madrid, reporting tumor responses, disease control and an FDA-aligned plan for a registra

What would management's 2028 goals make the stock worth by 2030?

Realty Income continues its long string of monthly dividend payments.

Booking's $9.1B free cash flow and 20% net margins face regulatory headwinds, while GameStop's fortress balance sheet and improving profitability signal a potential turnaround.

The new SpaceX SI data center cluster is going to run on the Nvidia Vera Rubin computer.

XRP has experienced periods of explosive growth before, but new investors should enter with reasonable expectations.

Women retiring at 62 collect significantly less than men, a gap that widens with age and reflects decades of earnings differences.

CitroTech (NYSEAMERICAN:CITR) is positioning its citric-acid-derived fire-retardant technology for use in wildfire prevention, wood products and residential property protection, Chief Executive Officer Wes Bolsen said during a presentation at the LD Micro conference. Bolsen, who became CEO about a

Alibaba's cloud expansion clashes with China's regulatory headwinds, while Booking's 20% net margin faces AI-driven competition and EU scrutiny.

Tech stocks are selling off as investors question the payoff of artificial intelligence (AI) infrastructure spending.

What's going on with Oklo?

Market pullbacks can be scary, but the right response is simpler than you think. Legendary investors agree on the winning playbook.